Quantcast
Last updated on April 20, 2014 at 1:20 EDT

Latest Parkinson's Stories

2012-10-07 22:20:23

AMSTERDAM, October 8, 2012 /PRNewswire/ -- Launch helps mark the voluntary organisation's 20th anniversary celebrations in Amsterdam The European Parkinson's Disease Association (EPDA) has launched the third and final booklet in its Life with Parkinson's series. This latest edition concludes a four-year awareness campaign, which aims to highlight the lack of understanding and knowledge concerning Parkinson's that exists throughout Europe today. The booklet's launch, in...

2012-09-14 10:23:34

NEW YORK, Sept. 14, 2012 /PRNewswire-USNewswire/ -- Todd Sherer, PhD, CEO of The Michael J. Fox Foundation for Parkinson's Research (MJFF), has been selected as one of 18 members of the Advisory Council to the newly formed National Center for Advancing Translational Sciences (NCATS) at the National Institute of Health (NIH). The NCATS Advisory Council, whose inaugural meeting takes place today in Bethesda, will provide insight and guidance on policies and procedures to overcome scientific...

2012-08-07 06:20:20

DANVILLE, Calif., Aug. 7, 2012 /PRNewswire/ -- Currently ranked as the third largest national supporter of the Michael J. Fox Foundation "TEAM FOX" efforts, the Danville d'Elegance Foundation (DDE) and its quest to support Parkinson's Research & Patient Care is on a roll. Since 2004, DDE and its staff of more than 200 volunteers, has raised more than $1.3 million to benefit the debilitating disease, while growing its annual weekend of events to include three separate car-related charity...

2012-08-01 06:20:24

DANVILLE, Calif., Aug. 1, 2012 /PRNewswire/ -- The annual Danville "Tour d'Elegance," returns for its 2nd year on Saturday, September 15, 2012, providing a day of driving, dining and most of all, car gazing, in support of Parkinson's research and patient care through the Danville d'Elegance (DDE) Foundation. This year's theme, "Legends of Racing, Heroes of Parkinson's," honors race car drivers David Love, Sam Posey and Phil Hill - all globally renowned, yet each one challenged with the...

2012-07-25 02:20:20

DANVILLE, Calif., July 25, 2012 /PRNewswire/ -- Ever wonder how it feels to own a GRAND-AM racing team -- or better yet, to feel the camaraderie and excitement as a member of a Rolex GT Sports Car team? Now you can get a "behind-the-scenes" look at GRAND-AM racing at the legendary Mazda Raceway Laguna Seca, with the Whelen/Marsh GT ("Grand Touring") and SunTrust DP ("Daytona Prototype") teams - and at the same time, support Parkinson's research and patient care. Veteran racer and...

2012-06-26 18:20:32

GRAND RAPIDS, Mich., June 27, 2012 /PRNewswire/ -- Van Andel Institute announces that researchers at Lund University in Sweden have published a study detailing how Parkinson's disease spreads through the brain. Experiments in rat models uncover a process previously used to explain mad cow disease, in which misfolded proteins travel from sick to healthy cells. "A major unmet medical need is a therapy that slows disease progression," said Patrik Brundin M.D., Ph.D., Jay Van Andel Endowed...

2012-06-25 06:32:16

NEW YORK, June 25, 2012 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research launched a completely revamped www.michaeljfox.org, the Foundation's first major Web site redesign in five years. The new Michaeljfox.org offers a streamlined user experience and dynamic content introducing the Foundation's research priorities, patient resources and opportunities for engagement. A rich taxonomy exposes content that may naturally live in one section but is relevant to...

2012-06-21 06:23:45

NEW YORK, June 21, 2012 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) today announced the opening of its Therapeutic Pipeline Program. This newly created funding mechanism invites research proposals from industry and academic investigators to drive pre-clinical and clinical Parkinson's disease drug development. MJFF has committed up to $14 million in funding toward three research programs, which include the Therapeutic Pipeline Program, Rapid...

2012-06-05 02:29:01

VIENNA, June 5, 2012 /PRNewswire/ -- The worldwide first clinical trial for the development of a Parkinson's vaccine has now been started by AFFiRiS AG. The vaccine called PD01A is directed against alpha-Synuclein, a protein considered causing the onset and progression of the disease, and is currently being tested on Parkinson's patients in a Phase I trial. The vaccine holds out the prospect to deliver a causative treatment of Parkinson's for the first time. Its potential for...

2012-05-17 02:25:20

SAN DIEGO, May 17, 2012 /PRNewswire/ -- Ceregene Inc., a biotechnology company developing treatments for neurodegenerative diseases such as Parkinson's disease, will present new data demonstrating long-term, biologically-active expression of neurturin, a nervous system growth factor delivered to the degenerating dopamine nerves in patients with Parkinson's disease following treatment with CERE-120 (AAV2-neurturin). Raymond T. Bartus, Ph.D., Ceregene's chief scientific officer and...